Skip to main content Accessibility help
×
Home
  • Print publication year: 2009
  • Online publication date: August 2010

Part 4 - Treatment of sleep disorders in the elderly

References

1. MorganK. Hypnotics in the elderly: what cause for concern?Drugs 1990;40:688–96.
2. AsplundR. Sleep and hypnotic use in relation to perceived somatic and mental health among the elderly. Arch Gerontol Geriatr 2000;31:199–205.
3. OhayonM, CauletM, LemoineP. The elderly, sleep habits and use of psychotropic drugs by the French population. Encephale 1996;5:337–50.
4. MorganK, DallossoH, EbrahimS, et al. Prevalence, frequency and duration of hypnotic use among elderly living at home. Br Med J 1988;296:601–2.
5. BrabbinsCJ, DeweyME, CopelandJRM, et al. Insomnia in the elderly: prevalence, gender differences and relationships with morbidity and mortality. Int J Geriatr Psychiatry 1993;8:473–80.
6. HendersonS, JormAF, ScottLR, et al. Insomnia in the elderly: its prevalence and correlates in the general population. Med J Aust 1995;162:22–4.
7. CriccoM, SimonsickEM, FoleyDJ. The impact of insomnia on cognitive functioning in older adults. J Am Geriatr Soc 2001;49(9):1185–9.
8. LivingstonG, BlizardB, MannA. Does sleep disturbance predict depression in elderly people? A study in inner London. Br J Gen Pract 1993;43:445–8.
9. AvidanAY, FriesBE, JamesML, et al. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. JAGS 2005;53:955–62.
10. KrystalAD. A compendium of placebo-controlled trials of the risks/benefits of pharmacologic treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev 2009;13:265–74.
11. GreenblattDJ, FriedmanH, BursteinES, et al. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther 1987;42(2):193–200.
12. GreenblattDJ, DivollMK, AbernethyDR, et al. Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. Pharmacology 1989;38(5):327–34.
13. GreenblattDJ, HarmatzJS, KarimA. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol 2007;47(4):485–96.
14. HayesB, Klein-SchwartzW, Barrueto JrF. Polypharmacy and the geriatric patient. Clin Geriatr Med 2007;23:371–90.
15. McCallWV, Erman, M, KrystalAD, et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006;22:1633–42.
16. ScharfM, SeidenD, ErmanM, et al. Eszopiclone rapidly induced sleep and provided sleep maintenance in elderly patients with chronic insomnia. Int Psychogeriatr 2003;15(2):200–1.
17. KrystalAD. Treating the health, quality of life, and functional impairments in insomnia. J Clin Sleep Med 2007;3:63–72.
18. KrystalAD, WalshJK, LaskaE, et al. Sustained efficacy of eszopiclone over six months of nightly treatment: results of a randomized, double-blind, placebo controlled study in adults with chronic insomnia. Sleep 2003;26:793–9.
19. WalshJK, KrystalAD, AmataDA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007;30(8):959–68.
20. MorinCM, ColecchiC, StoneJ, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999;281(11):991–9.
21. FavaM, McCallWV, KrystalA, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia co-existing with major depressive disorder. Biol Psychiatry 2006;59:1052–60.
22. PollackM, KinrysG, KrystalA, et al. Eszopiclone co-administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008;65(5):551–62.
23. WalshJK, MuehlbachMJ, LauterSA, et al. Effects of triazolam on sleep, daytime sleepiness, and morning stiffness in patients with rheumatoid arthritis. J Rheumatol 1996;23(2):245–52.
24. LebonO, MurphyJR, StanerL, et al. Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations. J Clin Psychopharmacol 2003;23(4):377–83.
25. KrygerM, RothT, Wang-WeigandS, et al. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep Breath 2009;13(1):79–84.
26. SteensRD, PouliotZ, MillarTW, et al. Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease. Sleep 1993;16(4):318–26.
27. TimmsRM, DawsonA, HajdukovicRM, et al. Effect of triazolam on sleep and arterial oxygen saturation in patients with chronic obstructive pulmonary disease. Arch Intern Med 1988;148(10):2159–63.
28. WalshJK. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep 2004;27(8):14441–2.
29. MurphySL. Deaths: final data for 1998. Natl Vital Stat Rep 2000;48:1–105.
30. AlexanderBH, RivaraFP, WolfME. The cost and frequency of hospitalization for fall-related injuries in older adults. Am J Public Health 1992;82:1020–3.
31. BrassingtonGS, KingAC, BliwiseDL. Sleep problems as a risk factor for falls in a sample of community- dwelling adults aged 64–99 years. J Am Geriatr Soc 2000;48:1234–40.
32. KoskiK, LuukinenH, LaippalaP, et al. Risk factors for major injurious falls among the home-dwelling elderly by functional abilities: a prospective population-based study. Gerontology 1998;44(4):232–8.
33. SuzukiM, OkamuraT, ShimazuY, et al. A study of falls experienced by institutionalized elderly. Nippon Koshu Eisei Zasshi 1992;39(12):927–40.
34. NebesRD, PollockBG, HalliganEM, et al. Serum anticholinergic activity and motor performance in elderly persons. J Gerontol A Biol Sci Med Sci 2007;62(1):83–5.
35. AllainH, Bentué-FerrerD, PolardE, et al. Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging 2005;22(9):749–65.
36. KoskiK, LuukinenH, LaippalaPet al. Physiological factors and medications as predictors of injurious falls by elderly people: a prospective population-based study. Age Ageing 1996;25:29–38.
37. MustardCA, MayerT. Case-control study of exposure to medication and the risk of injurious falls requiring hospitalization among nursing home residents. Am J Epidemiol 1997;145:738–45.
38. NeutelCI, PerryS, MaxwellC. Medication use and risk of falls. Pharmacoepidemiol Drug Safety 2002;11:97–104.
39. StenbackaM, JanssonB, LeifmanA, et al. Association between use of sedatives or hypnotics, alcohol consumption, or other risk factors and a single injurious fall or multiple injurious falls: a longitudinal general population study. Alcohol 2002;28:9–16.
40. TinettiME, SpeechleyM, GinterSF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988;319:1701–7.
41. SobelKG, McCartGM. Drug use and accidental falls in an intermediate care facility. Drug Intell Clin Pharm 1983;17(7–8):539–42.
42. Ancoli-IsraelS, RichardsonGS, ManganoRM, et al. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005;6(2):107–13.

References

1. Wikipedia. Laudanum. http://en.wikipedia.org/wiki/Laudanum.
2. Wikipedia. Bromide. http://en.wikipedia.org/wiki/Bromide.
3. NeutelCI, WalopW, AppelCW. Triazolam and the potential for violence: the need for an epidemiological study. Can Pharm J 1992;216:214–7.
4. LiebermanJA. Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Prim Care Companion J Clin Psychiatry 2007;9(1):25–31.
5. WagnerJ, WagnerML. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev 2000;4:551–81.
6. BellonA. Searching for new options for treating insomnia: are melatonin and ramelteon beneficial?J Psychiatr Pract 2006;12(4):229–43.
7. RoehrsT, RothT. Sleep, sleepiness and alcohol use. Alcohol Res Health 2001;25(2):101–9.
8. RoehrsT, HollebeekE, DrakeC, RothT. Substance use for insomnia in Metropolitan Detroit. J Psychosom Res 2002;53(1):571–6.
9. RoehrsT, BurduvaliE, BonahoomA, DrakeC, RothT. Ethanol and sleep loss: a “dose” comparison of impairing effects. Sleep 2003;26(8):981–5.
10. WHO Collaborating Centre for Drug Statistics Methodology/Nordic Council on Medicines. Guidelines for ATC Classification. Oslo, 1990.
11. Patented Medicine Prices Review Board. ATC Classification System for Human Medicines. Ottawa: Patented Medicine Prices Review Board; 1994.
12. WalopW, SemenchukM. Coding of drugs used by respondents of the Canadian study of health and aging. Can J Clin Pharmacol 2002;9:64–8.
13. NeutelCI. The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry 2005;17(3):189–97.
14. BustoUE, SprouleBA, KnightK, HerrmannN. Use of prescription and nonprescription hypnotics in a Canadian elderly population. Can J Clin Pharmacol 2001;8(4):213–21.
15. BarbuiC, GregisM, ZappaM. A cross-sectional audit of benzodiazepine use among general practice patients. Acta Psychiatr Scand 1998;97:153–6.
16. BalkrishnanR, RasuRS, RajagopalanR. Physician and patient determinants of pharmacologic treatment of sleep difficulties in outpatient settings in the United States. Sleep 2005;28(6):715–19.
17. OhayonMM, CauletM. Insomnia and psychotropic drug consumption. Prog Neuropsychopharmacol Biol Psychiatry 1995;19(3):421–31.
18. FourrierA, LetenneurL, DartiguesJF, MooreN, BegaudB. Benzodiazepine use in an elderly community-dwelling population: characteristics of users and factors associated with subsequent use. Eur J Pharmacol 2001;57:419–25.
19. NeutelCI, WalopW. Drug utilization by men and women: why the difference?Drug Inf J 2005;39:299–310.
20. RothT, RoehrsT. Insomnia: epidemiology, characteristics, and consequences. Clin Cornerstone 2003;5(3):5–15.
21. BarbuiC, CampomoriA, MezzaliraL, et al. Psychotropic drug use in Italy, 1984–1999: the impact of a change in reimbursement status. Int Clin Psychopharmacol 2001;16:227–33.
22. MendelsonWB, RothT, CassellaJ, et al. The treatment of chronic insomnia: drug indications, chronic use and abuse liability: summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med Rev 2004;8:7–17.
23. OhayonMM, CauletM. Psychotropic medication and insomnia complaints in two epidemiological studies. Can J Psychiatry 1996;41(7):457–64.
24. BencaRM. Diagnosis and treatment of chronic insomnia: a review. Psychiatr Serv 2005;56(3):332–43.
25. Ancoli-IsraelS, PocetaJS, StepnowskyC, MartinJ, GehrmanP. Identification and treatment of sleep problems in the elderly. Sleep Med Rev 1997;1(1):3–17.
26. ShochatT, LoredoJ, Ancoli-IsraelS. Sleep disorders in the elderly. Curr Treat Options Neurol 2001;3(1):19–36.
27. RoehrsT, RothT. Sleep and pain: interaction of two vital functions. Semin Neurol 2005;25(1):106–16.
28. TuK, MamdaniMM, HuxJE, TuJB. Progressive trends in the prevalence of benzodiazepine prescribing in older people in Ontario, Canada. J Am Geriatr Soc 2001;49(10):1341–5.
29. BartlettG, AbrahamowiczM, TamblynR, et al. Longitudinal patterns of new benzodiazepine use in the elderly. Pharmacoepidemiol Drug Saf 2004;13(10):669–82.
30. TuK, MamdaniMM, HuxJE, TuJB. Progressive trends in the prevalence of benzodiazepine prescribing in older people in Ontario, Canada. J Am Geriatr Soc 2001;49:1341–5.
31. LaderM. Zopiclone: is there any dependence and abuse potential?J Neurol 1997;244(4 Suppl. 1):S18–22.
32. SchweizerE, RickelsK, CaseWG, GreenblattDJ. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry 1990;47:908–15.
33. BustoU, SellersEM, NaranjoCA, et al. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 1986;315:854–9.
34. RickelsK, SchweizerE, CaseWG, GreenblattDJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 1990;47:899–907.
35. HajakG, ClarenbachP, FisherW, et al. Rebound insomnia after hypnotic withdrawal in insomniac outpatients. Eur Arch Psychiatry Clin Neurosci 1998;248:148–56.
36. BustoU, SellersEM. Pharmacological aspects of benzodiazepine tolerance and dependence. J Subst Abuse Treat 1991;8:29–33.
37. BatesonAN. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharm Des 2002;8:5–21.
38. BarterG, CormackM. The long-term use of benzodiazepines: patients’ views, accounts and experiences. Fam Pract 1996;13:491–7.
39. SprouleBA, BustoUE, BuckleC, HerrmannN, BowlesS. The use of non-prescription sleep products in the elderly. Int J Geriatr Psychiatry 1999;14(10):851–7.
40. MahL, UpshurRE. Long term benzodiazepine use for insomnia in patients over the age of 60: discordance of patient and physician perceptions. BMC Fam Pract 2002;3:9–15.
41. LindenM, BarT, GeiselmannB. Patient treatment insistence and medication craving in long-term low-dosage benzodiazepine prescriptions. Psychol Med 1998;28:721–9.
42. WinkelmanJ, PiesR. Current patterns and future directions in the treatment of insomnia. Ann Clin Psychiatry 2005;17(1):31–40.
43. JeffersonCD, DrakeCL, ScofieldHM, et al. Sleep hygiene practices in a population-based sample of insomniacs. Sleep 2005;28(5):611–5.
44. DamestoyN, CollinJ, LalandeR. Prescribing psychotropic medication for elderly patients: some physicians’ perspectives. Can Med Assoc J 1999;161:143–5.
45. PimlottNJ, HuxJE, WilsonLM, et al. Educating physicians to reduce benzodiazepine use by elderly patients: a randomized controlled trial. CMAJ 2003;168:835–9.
46. McNuttLA, ColesFB, McAuliffeT, et al. Impact of regulation on benzodiazepine prescribing to a low income elderly population, New York State. J Clin Epidemiol 1994;47(6):613–25.
47. WeintraubM, SinghS, ByrneL, MaharajiK, GuttmacherL. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA 1991;266:2392–7.
48. ZullichSG, GraselaTH Jr, Fiedler-KellyJB, GengoFM. Impact of triplicate prescription program in psychotropic prescribing patterns in long-term care facilities. Ann Pharmacother 1992;26:539–46.
49. MendelsonWB, JainB. An assessment of short-acting hypnotics. Drug Saf 1995;13(4):257–70.
50. HolbrookAM, CrowtherR, LotterA, ChengC, KingD. The diagnosis and management of insomnia in clinical practice: a practical evidence-based approach. CMAJ 2000;162(2):216–20.

References

1. MontiJM. Sleep laboratory and clinical studies of the effects of triazolam, flunitrazepam and flurazepam in insomniac patients. Meth Find Exp Clin Pharmacol 1981;3:303–26.
2. National Sleep Foundation. Sleep in America: A National Survey of U.S. Adults. Princeton, N.J.: The Gallup Organization; 1991.
3. Ancoli-IsraelS, RothT. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. Sleep 1999;22(Suppl. 2):347–53.
4. HohagenF, RinkK, KäpplerC, et al. Prevalence and treatment of insomnia in general practice: a longitudinal study. Eur Arch Psychiat Clin Neurosci 1993;242:329–36.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, revised, 3rd ed. Washington D.C.: American Psychiatric Press; 1987.
6. WeyererS, DillingH. Prevalence and treatment of insomnia in the community: results from the upper Bavarian Field Study. Sleep 1991;14:392–8.
7. BalterMB, UhlenhuthEH. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry 1992;53(Suppl. 12):34–9.
8. LugaresiE, CirignottaF, ZucconiM, et al. Good and poor sleepers: an epidemiological survey of the San Marino population. In GuilleminaultC, LugaresiE, eds. Sleep/Wake Disorders: Natural History, Epidemiology, and Long-Term Evolution. New York: Raven Press; 1983; pp. 1–12.
9. FoleyDJ, MonjanAA, BrownSL, et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 1995;18:425–32.
10. Cornoni-HuntleyJC, OstfeldAM, TaylorJO, et al. Established populations for epidemiologic studies of the elderly: study design and methodology. Aging Clin Exp Res 1993;5:27–37.
11. FoleyDJ, MonjanA, SimonsickEM, WallaceRB, BlazerDG. Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6800 persons over three years. Sleep 1999;22(Suppl. 2):366–72.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington D.C.: American Psychiatric Press; 1994.
13. LichsteinKL. Secondary insomnia. In LichsteinKL, MorinCD. eds. Treatment of Late-Life Insomnia. Thousand Oaks: Sage Publications; 2000; pp. 297–319.
14. American Sleep Disorders Association. International Classification of Sleep Disorders, Revised: Diagnostic and Coding Manual. Rochester MN: American Sleep Disorders Association; 1997.
15. BonnetMH, ArandDL. Hyperarousal and insomnia. Sleep Med Rev 1997;1:97–108.
16. McCraeCS, LichsteinKL. Secondary insomnia: diagnostic challenges and intervention opportunities. Sleep Med Rev 2001;5:47–61.
17. HarveySC. Hypnotics and sedatives: the barbiturates. In GoodmanLS, GilmanA, eds. The Pharmacological Basis of Therapeutics. New York: MacMillan; 1975; pp. 102–23.
18. MontiJM. Primary and secondary insomnia: prevalence, causes and current therapeutics. Curr Med Chem – CNS Agents 2004;4:119–37.
19. AtorNA, McCannUD. New insights into the GABAA receptor. CNS Spectr 2005;10:20.
20. SangerDJ. The pharmacology and mechanism of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 2004;18(Suppl. 1):9–15.
21. MuschB, MaillardF. Zopiclone, the third generation hypnotic: a clinical overview. Int Clin Psychopharmacol 1990;5:147–58.
22. NajibJ. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin. Ther 2006;28:491–516.
23. ThénotJP, HermannP, DurandA., et al. Pharmacokinetics and metabolism of zolpidem in various animal species and in humans. In SauvanetJP, LangerSZ, MorselliPL, eds. Imidazopyridines in Sleep Disorders. New York: Raven Press; 1988; pp. 139–53.
24. BianchettiG, DubrucC, ThiercelinJF, et al. Clinical pharmacokinetics of zolpidem in various physiological and pathological conditions. In SauvanetJP, LangerSZ, MorselliPL, eds. Imidazopyridines in Sleep Disorders. New York: Raven Press; 1988; pp. 155–63.
25. HurstM, NobleS. Zaleplon. CNS Drugs 1999;11:387–92.
26. RosenAS, FourniéP, DarwishM, DanjouP, TroySM. Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Disp 1999;20:171–5.
27. DooleyM, PloskerGL. Zaleplon: a review of its use in the treatment of insomnia. Drugs 2000;60:413–45.
28. MamelakM, ScimaA, PriceV. Efficacy of zopiclone on the sleep of chronic insomniacs. Pharmacology 1983;27(Suppl. 2):136–45.
29. QuadensOP, HoffmanG, BuytaertG. Effects of zopiclone as compared to flurazepam in women over 40 years of age. Pharmacology 1983;27(Suppl. 2):146–55.
30. PecknoldJ, WilsonR, Le MorvanP. Long-term effects and withdrawal of zopiclone. Int Clin Psychopharmacol 1990;5(Suppl. 2):57–67.
31. BilliardM, BessetA, De LustracC, BrissaudL. Dose-response effects of zopiclone on night sleep and on night and daytime functioning. Sleep 1987;10:27–34.
32. TibergeM, CalvetV, KhayiN. Comparison des effets de la zopiclone et du triazolam sur le sommeil du sujet sain. Encéphale 1992;14:319–24.
33. JovanovicUJ, DreyfusJF. Polygraphical sleep recordings in insomniac patients under zopiclone or nitrazepam. Pharmacology 1983;27(Suppl. 2):136–45.
34. NobleS, LangtryHD, LambHM. Zopiclone: an update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1998;55:277–302.
35. ZammitGK, McNabbLJ, CaronJ, AmatoDA, RothT. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20:1979–91.
36. KrystalAD, WalshJK, LaskaE, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793–9.
37. MontiJM, AttaliP, MontiD, et al. Zolpidem and rebound insomnia – a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 1994;27:166–75.
38. HerrmannWM, KubickiS, WoberW. Zolpidem: a four-week pilot polysomnographic study in patients with chronic sleep disturbances. In SauvanetJP, LangerSZ, MorselliPL, eds. Imidazopyridines in Sleep Disorders. New York: Raven Press; 1988: pp. 261–78.
39. MontiJM. Effects of zolpidem on sleep in insomniac patients. Eur J Clin Pharmacol 1989;36:461–6.
40. MontiJM, MontiD, EstévezF, GiustiM. Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal. Int Clin Psychopharmacol 1996;11:255–63.
41. SauvanetJP, MaarekL, RogerM, et al. Open long-term trials with zolpidem in insomnia. In SauvanetJP, LangerSZ, MorselliPL, eds. Imidazopyridines in Sleep Disorders. New York: Raven Press; 1988; pp. 339–49.
42. ScharfMB, MendelsJ, ThorpyM, WeissB. Safety and long-term zolpidem treatment in insomniacs. Curr Ther Res 1994;55:1100–11.
43. WalshJK, RothT, RandazzoA, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000; 23:1087–96.
44. RothT, SoubraneC, TiteuxL, WalshJK. Efficacy and safety of zolpidem-MR: A double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006;7:397–406.
45. HeydornWE. Zaleplon – a review of a novel sedative hypnotic used in the treatment of insomnia. Exp Opin Invest Drugs 2000;9:841–58.
46. WalshJK, FryJ, RichardsonGS, ScharfMB, VogelGW. Short-term efficacy of zaleplon in older chronic insomnia patients. Clin Drug Invest 2000;20:143–9.
47. ElieR, RutherE, FarrI, EmilienG, SalinasE. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel non-benzodiazepine hypnotic. Clin Psychiatry 1999;60:536–44.
48. ElieR, DeschenesJ-P. Efficacy and tolerance of zopiclone in insomniac geriatric patients. Pharmacology 1983;27(Suppl. 2):179–87.
49. VenterCP, JoubertPH, StahmerSD, VenterMR, SharkeyJ. Zopiclone compared with triazolam in insomnia in geriatric patients. Cur Ther Res 1986;40:1062–86.
50. KlimmHD, DreyfusJF, DelmotteM. Zopiclone versus nitrazepam: a double-blind comparative study of efficacy and tolerance in elderly patients with chronic insomnia. Sleep 1987;10(Suppl. 1):73–8.
51. ElieR, FrenayM, Le MorvanP, BourgouinJ. Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychopharmacol 1990;5(Suppl. 2):39–46.
52. HemmeterU, MüllerM, BischofR, AnnenB, Holsboer-TrachslerE. Effect of zopiclone and temazepam on sleep EEG parameters, psychomotor and memory functions in healthy elderly volunteers. Psychopharmacology 2000;147:384–96.
53. ScharfM, ErmanM, RosenbergR, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005;28:720–7.
54. McCallWV, Erman, M, KrystalAD, et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006;22:1633–42.
55. RogerM, DallotJY, SalmonO, et al. Hypnotic effect of zolpidem in geriatric patients: a dose-finding study. In SauvanetJP, LangerSW, MorselliPL, eds. Imidazopyridines in Sleep Disorders. New York: Raven Press;1988: pp. 279–95.
56. De DomenicoP, SivestriR, Di PerriR. Terapia dell´insonnia in etá geriatrica: studio clinico con zolpidem, ipnotico a struttura imidazopiridinica. Argomenti di Neurologia 1991;1:197–205.
57. DolencL, VujicD, VodusekDB, et al. Multicenter double-blind study of zolpidem and triazolam in the treatment of chronic insomnia in the elderly. Sleep 1998;21(Suppl.):135.
58. RogerM, AttaliP, CoquelinJP. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Ther 1993;15:127–36.
59. EmeriauJP, DescampsA, DechelotteP, et al. Zolpidem and flunitrazepam: a multicenter trial in elderly hospitalized patients. In SauvanetJP, LangerSZ, MorselliPL, eds. Imidazopyridines in Sleep Disorders. New York: Raven Press; 1988: pp. 317–26.
60. LegerD, RogerM, GerardD. Sommeil et rythme de vie d´une population de personnes âgées insomniaques. Rev Geriat 1998;23:73–84.
61. BiondiF, CasadeiGL. Results of a multicenter trial with the hypnotic zolpidem in 1152 insomniac patients. Curr Ther Res 1994;55:262–74.
62. SchlichD, L´HeritierC, CoquelinJP, AttaliP, KryreinHJ. Long-term treatment of insomnia with zolpidem: a multicenter general practitioner study of 107 patients. J Int Med Res 1991;19:271–9.
63. FairweatherDB, KerrJS, HindmarchI. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol 1992;43:597–601.
64. OchsRF, FillingimJ, CutlerN, et al. The effect of zolpidem in elderly patients with chronic insomnia. J Sleep Res 1992;1(Suppl. 1):164.
65. ShawSH, CursonH, CoquelinJP. A double-blind comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1992;20:150–61.
66. KummerJ, GuendelL, LindenJ, et al. Long-term polysomnographic study of the efficacy and safety of zolpidem in elderly psychiatric in-patients with insomnia. J Int Med Res 1993;21:171–84.
67. Ancoli-IsraelS, WalshJK, ManganoRM, FujimoriM. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. J Clin Psychiatry 1999;1:114–20.
68. AllainH, DelahayeC, Le CozF, et al. Postmarketing surveillance of zopiclone in insomnia: analysis of 20,513 cases. Sleep 1991;14:408–13.
69. MontiJM, Pandi-PerumalSR. Eszopiclone: its use in the treatment of insomnia. Neuropsychiat Dis Treat 2007;3:441–53.
70. HindmarchI, HallerJ, SherwoodN, KerrJS. Comparison of five anxiolytic benzodiazepines on measures of psychomotor performance and sleep. Neuropsychobiology 1990;91:84–9.
71. KuitunenT, MattilaMJ, SeppalaT. Actions and interactions of hypnotics on human performance: single doses of zopiclone, triazolam and alcohol. Int J Psychopharmacol 1990;5(Suppl. 2):115–30.
72. MontiJM, MontiD. Overview of currently available benzodiazepine and nonbenzodiazepine hypnotics. In Pandi-PerumalSR, MontiJM, eds. Clinical Pharmacology of Sleep. Zurich: Birkhäuser; 2006: pp. 207–23.

References

1. GlassJ, LanctotKL, Herrmann, N, et al. Sedative hypnotics in older people with insomnia; meta-analysis of risks and benefits. BMJ 2005;331:1169–73.
2. Ancoli-IsraelS. Sleep and aging: prevalence of disturbed sleep and treatment considerations in older adults. J Clin Psychiatry 2005;66(Suppl. 9):24–30.
3. ByrneJ. Insomnia in older people: current approaches to treatment. Prescriber 2006;19 June:54–6.
4. DrakeCL, RoehrsT, RothT. Insomnia causes, consequences, and therapeutics: an overview. Depression Anxiety 2003;18:163–76.
5. CastledenCM, GeorgeCF, MarcerD, HallettC. Increased sensitivity to nitrazepam in old age. BMJ 1977;1:10–2.
6. KamelNS, GammackJK. Insomnia in the elderly: cause, approach, and treatment. Am J Med 2006;119:463–9.
7. National Institutes of Health State-of-the-Art Conference Statement. Final Statement 18 August, 2005. Available at http://consensus.nih.gov/2005/2005insomniaS0S026html.htm. Accessed 24 September, 2007.
8. LachnitK, ProszolowskiE, RiederL. Midazolam in the treatment of sleep disorders in geriatric patients. Br J Clin Pharmacol 1983;16(Suppl.):173–7S.
9. MamelakM, CsimaA, BuckL, PriceV. A comparative study on the effects of brotizolam and flurazepam on sleep and performance in the elderly. J Clin Psychopharm 1989;9:260–7.
10. RichardsHH, Valle-JonesCJ. A double-blind comparison of two lormetazepam doses in elderly insomniacs. Curr Med Res Opin 1988;11:48–55.
11. BayerA, PathyMSJ. Clinical and psychometric evaluation of 2 doses of loprazolam and placebo in geriatric patients. Curr Med Res Opin 1986;10:17–24.
12. CaldwellJR. Short-term quazepam treatment of insomnia in geriatric patients. Pharmatherapeutica 1982;3:278–82.
13. RothT, RoehrsTA, KsohorekGL, et al. Hypnotic effects of low doses of quazepam in older insomniacs. J Clin Psychopharmacol 1997;17:401–6.
14. FairweatherDB, KerrJS, HindmarchI. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol 1992;43:597–601.
15. NajibJ. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther 2006;28:491–516.
16. ErmanM, RosenbergR, CaronY. Polysomnographic and patient-reported evaluation of the efficacy and safety of eszopiclone in elderly subjects with chronic insomnia. Sleep 2004;27(Suppl. 6):257–8.
17. ScharfM, ErmanM, RosenbergR, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005;28:720–7.
18. HednerJ, YaecheR, EmilienG, FarrI, SalinasE. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry 2000;15:704–12.
19. OverstallP, OldmanPN. A comparative study of lormetazepam and chlormethiazole in elderly in-patients. Age Ageing 1987;16:45–51.
20. CookPJ, HuggettA, Grahame-PoleR, et al. Hypnotic accumulation and hangover in elderly inpatients: a controlled double-blind study of temazepam and nitrazepam. BMJ 1983;286:100–2.
21. MurphyP, HindmarchI, HylandCM. Aspects of short-term use of two benzodiazepine hypnotics in the elderly. Age Ageing 1982;11:222–8.
22. ReevesR. Comparison of triazolam, flurazepam, and placebo as hypnotics in geriatric patients with insomnia. J Clin Pharmacol 1977;17:319–23.
23. BayerAJ, PathyMS, AnkierSI. An evaluation of the short-term hypnotic efficacy of loprazolam in comparison with nitrazepam in elderly patients. Pharmatherapeutica 1983;3:468–74.
24. DehlinO, BjornsonJ. Triazolam as a hypnotic for geriatric patients. Act Psychiatr Scand 1983;67:290–6.
25. MouretJ, RuelD, MaillardF, BianchiM. Zopiclone versus triazolam in insomniac geriatric patients: a specific increase in delta sleep with zopiclone. Int Clin Psychopharmacol 1990;5(Suppl. 2):47–55.
26. DehlinO, RubinB, RundgrenA. Double-blind comparison of zopiclone and flunitrazepam in elderly insomniacs with special focus on residual effects. Curr Med Res Opin 1995;13:317–24.
27. ElieR, FrenayM, Le MorvanP, BourgouinJ. Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychopharmacol 1990;5(Suppl. 2):39–46.
28. HindmarchI, LegangeuxE, NeilS, et al. A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers. Br J Clin Pharmacol 2006;62:538–45.
29. PathyMSJ, BayerAJ, StokerMJ. A double-blind comparison of chlormethiazole and temazepam in elderly patients with sleep disturbances. Acta Psychiatrica Scand 1986;73(Suppl. 329):99–103.
30. BayerAJ, BayerEM, PathyMSJ, StokerMJ. A double-blind study of chlormethiazole and triazolam as hypnotics in the elderly. Acta Psychiatrica Scand 1986;73(Suppl. 329):104–11.
31. SivertsenB, OmvikS, PallesenS, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia. JAMA 2006;295:2851–8.
32. MorinC, ColecchiC, StoneJ, SoodR, BrinkD. Behavioural and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999;281:991–9.
33. VermeerenA. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004;18:297–328.
34. VogelG. Clinical uses and advantages of low doses of benzodiazepine hypnotics. J Clin Psychiatry 1992;53(suppl):19–22.
35. SoldatosCR, DikeosDG, WhiteheadA. Tolerance and rebound with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. J Clin Psychopharmacol 1999;14:287–303.
36. LaderM. Withdrawal reactions after stopping hypnotics in patients with insomnia. CNS Drugs 1998;10:425–40.
37. LaderM. Rebound and withdrawal with benzodiazepine and non-benzodiazepine hypnotic medication. In Pandi-PerumalSR, MontiJM, eds Clinical Pharmacology of Sleep. Basel: Birkhauser; 2006: pp. 225–5.
38. BainKT. Management of chronic insomnia in elderly persons. Am J Geriatr Pharmacother 2006;4:168–92.
39. DolderC, NelsonM, McKinseyJ. Use of non-benzodiazepine hypnotics in the elderly: are all agents the same?CNS Drugs 2007;21:389–405.
40. Anonymous. What’s wrong with prescribing hypnotics?Drug Ther Bull 2004;42:89–93.

References

1. Federal Interagency Forum on Aging-Related Statistics. Older Americans Update 2006: Key Indicators Of Well-Being. Available online at http://www.agingstats.gov/
2.Insee. Population par groupe d’âge dans le mondeUpdate 2007. Available online at http://www.insee.fr/fr/ffc/chifcle_fiche.asp?tab_id=340
3. TamblynRM, McLeodPJ, AbrahamowiczM, et al. Questionable prescribing for elderly patients in Quebec. Can Med Assoc J 1994;150(11):1801–9.
4. SheltonPS, FritschMA, ScottMA. Assessing medication appropriateness in the elderly: a review of available measures. Drugs Aging 2000;16(6):437–50.
5. National Academia of Pharmacy. Personnes Agées et Médicaments Report 2005. Available online at http://www.acadpharm.org/medias/direct/Agees.pdf
6. Carrasco-GarridoP, Jiménez-GarciaR, Astasio-ArbizaP, Ortega-MolinaP, Gil de MiguelA. Psychotropics use in the Spanish elderly: predictors and evolution between years 1993 and 2003. Pharmacoepidemiol Drug Saf 2007;16:449–57.
7. FourrierEJP, DartiguesJF, BegaudB. Prescription médicamenteuse chez les personnes âgées. Bull Acad Natl Med 1998;182:1419–29.
8. Salles-MontaudonN, FourrierA, DartiguesJF, RainfrayM, EmeriauJP. Evolution des traitements médicamenteux des personnes âgées vivant à domicile. Rev Méd Interne 2000;21:664–71.
9. LinjakumpuT, HartikainenS, KlaukkaT, et al. Psychotropics among the home-dwelling elderly: increasing trends. Int J Geriatr Psychiatry 2002;17:874–83.
10. JyrkkäJ, VartiainenL, HartikainenS, SulkavaR, EnlundH. Increasing use of medicines in elderly persons: a five-year follow-up of the Kuopio 75+ study. Eur J Clin Pharmacol 2006;62:151–8.
11. DealbertoMJ, SeemanT, McAvayGJ, BerkmanL. Factors related to current and subsequent psychotropic drug use in an elderly cohort. J Clin Epidemiol 1997;50:357–63.
12. PrévilleM, HébertR, BoyerR, BravoG. Correlates of psychotropic drug use in the elderly compared to adults aged 18–64: results from the Quebec Health Survey. Aging Ment Health 2001;5:216–24.
13. OuelletN, BeaulieuM. Psychosocial factors related to the use of psychotropic drugs in elderly persons. Rech Soins Infirm 2003;74:38–46.
14. Paulose-RamR, JonasBS, OrwigD, SafranMA. Prescription psychotropic medication use among the U.S. adult population: results from the third national health and nutrition examination survey, 1988–1994. J Clin Epidemiol 2004;57:309–17.
15. BeckCA, WilliamsJVA, WangJL, et al. Psychotropic medication use in Canada. Can J Psychiatry 2005;50:605–13.
16. ESEMed Project. Psychotropic drug utilization in Europe: results from the European study of the epidemiology of mental disorders (ESEMeD) project. Acta Psychiatr Scand 2004;109(Suppl. 420):55–64.
17. HartikainenS, RahkonenT, KautiainenH, SulkavaR. Kuopio 75+ study: does advanced age predict common use of psychotropics among the elderly. Int Clin Psychopharmacol 2003;18:163–7.
18. LindenM, BärT, HelmchenH. Prevalence and appropriateness of psychotropic drug use in old age: results from the Berlin Aging Study (BASE). Int Psychogeriatr 2004;16:461–80.
19. RapoportM, MamdaniM, ShulmanKI, HerrmannN, RochonPA. Antipsychotic use in the elderly: shifting trends and increasing costs. Int J Geriatr Psychiatry 2005;20:749–53.
20. Pérez BenitezCA, SmithK, VasileRG, et al. Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders. Am J Geriatr Psychiatry 2008;16:5–13.
21. TuK, MamdaniMM, HuxJE, TuJun-bi. Progressive trends in the prevalence of benzodiazepine prescribing in older people in Ontario, Canada. J Am Geriatr Soc 2001;49:1341–5.
22. MamdaniMM, ParikhS, AustinPC, UpshurREG. Use of antidepressants among elderly subjects: trends and contributing factors. Am J Psychiatry 2000;157:360–7.
23. MamdaniMM, RapaportM, ShulmanKI, HerrmannN, RochonPA. Mental health-related drug utilization among older adults: prevalence, trends, and costs. Am J Geriatr Psychiatry 2005;13:892–900.
24. FoleyDJ, MonjanAA, BrownSL, et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 1995;18:425–32.
25. HarringtonJJ, AvidanAY. Treatment of sleep disorders in elderly patients. Curr Treat Options Neurol 2005;7:339–52.
26. Van DijkKN, de VriesCS, ter HuurneK, et al. Concomitant prescription of benzodiazepines during antidepressant therapy in the elderly. J Clin Epidemiol 2002;55:1049–53.
27. KirbyM, DenihanA, BruceI, et al. Benzodiazepine use among the elderly in the community. Int J Geriat Psychiatry 1999;14:280–4.
28. StickgoldR. Human studies of sleep and off-line memory reprocessing. In MaquetP, SmithC, StickgoldR, eds. Sleep and Brain Plasticity. New York: Oxford University Press; 2003: pp. 41–63.
29. HobsonAJ, Pace-SchottEF, StickgoldR. Dreaming and the brain: toward a cognitive neuroscience of conscious states. In Pace-SchottEF, SolmsM, BlagroveM, HarnadS, eds. Sleep and Dreaming. Cambridge: Cambridge University Press; 2003: pp. 1–50.
30. DestexheA, HughesSW, RudolphM, CrunelliV. Are corticothalamic ‘up’ states fragments of wakefulness?Trends Neurosci 2007;30:334–42.
31. CrenshawMC, EdingerJD. Slow-wave sleep and waking cognitive performance among older adults with and without insomnia complaints. Physiol Behav 1999;66:485–92.
32. AndersonC, HorneJA. Prefrontal cortex: links between low frequency delta EEG in sleep and neuropsychological performance in healthy, older people. Psychophysiology 2003;40:349–57.
33. Pace-SchottEF, HobsonJA. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nature Neurosci 2002;3:591–605.
34. SteriadeM. Grouping of brain rhythms in corticothalamic systems. Neuroscience 2006;137:1087–106.
35. OhayonMM, CarskadonMA, GuilleminaultC, VitielloMV. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep 2004;27:1255–73.
36. DijkDJ, DuffyJF, CzeislerCA. Age-related increase in awakenings: impaired consolidation of nonREM sleep at all circadian phases. Sleep 2001;24:565–77.
37. DuffyJF, ZeitzerJM, RimmerDW. Peak of the circadian melatonin rhythm occurs later within the sleep in older subjects. Am J Physiol Endocr Metab 2002;282:E297–E303.
38. BuysseDJ, MonkTH, CarrierJ, BegleyA. Circadian patterns of sleep, sleepiness, and performance in older and younger adults. Sleep 2005;28:1365–76.
39. RedlineS, KirchnerHL, QuanSF, et al. The effects of age, sex, ethnicity, and sleep-disordered breathing on sleep architecture. Arch Intern Med 2004;164:406–18.
40. NicolasA, PetitD, RompréS, MontplaisirJ. Sleep spindles characteristics in healthy subjects of different age groups. Clin Neurophysiol 2001;112:521–7.
41. BliwiseDL. Normal aging. In: KrygerMH, RothT, DementWC, eds. Principles and Practice of Sleep Medicine,4th ed. Philadelphia: Elsevier; 2005: pp. 24–38.
42. DarchiaN, CampbellIG, FeinbergI. Rapid eye movement density is reduced in normal elderly. Sleep 2003;26:973–7.
43. SangerDJ. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 2004;18:9–15.
44. RudolphU, CrestaniF, BenkeD, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999;401:796–800.
45. HaasH, PanulaP. The role of histamine and the tuberomammilary nucleus in the nervous system. Nat Rev Neurosci 2003;4:121–30.
46. SergeevaOA, EriksonKS, SharanovaIN, VorobjevVS, HaasHL. GABA(A) receptor heterogeneity in histaminergic neurons. Eur J Neurosci 2002;16:1472–82.
47. NelsonLE, GuoTZ, LuJ, et al. The sedative component of anaesthesia is mediated by GABA(A) receptors in endogenous sleep pathway. Nat Neurosci 2002;5:979–84.
48. LandoltHP, GillinJC. GABAA1a receptors: involvement in sleep regulation and potential of selective agonists in the treatment of insomnia. CNS Drugs 2000;13:185–99.
49. FeinbergI, MaloneyT, CampbellIG. Effects of hypnotics on the sleep EEG of healthy young adults: new data and psychopharmacologic implications. J Psychiatr Res 2000;34:423–38.
50. FrostJD Jr, DeLucchiMR. Insomnia in the elderly: treatment with flurazepam hydrochloride. J Am Geriatr Soc 1979;27:541–6.
51. CarskadonMA, SeidelWF, GreenblattDJ, DementWC. Daytime carryover of triazolam and flurazepam in elderly insomniacs. Sleep 1982;5:361–71.
52. VogelGW. Sleep laboratory study of lormetazepam in older insomniacs. Psychopharmacology 1984;1(Suppl.):69–78.
53. RoehrsT, ZorickF, WittigR, RothT. Efficacy of a reduced triazolam dose in elderly insomniacs. Neurobiol Aging 1985;6:293–6.
54. AdamK, OswaldI. A comparison of the effects of chlormezanone and nitrazepam on sleep. Br J Clin Sci 1982;14:57–65.
55. VogelGW, MorrisD. The effects of estazolam on sleep, performance, and memory: a long-term sleep laboratory study of elderly insomniacs. J Clin Pharmacol 1992;32:647–51.
56. RothTG, RoehrsTA, KoshorekGL, GreenblattDJ, RosenthalLD. Hypnotic effects of low doses of quazepam in older insomniacs. J Clin Psychopharmacol 1997;17:401–6.
57. SteensRD, PouliotZ, MillarTW, KrygerMH, GeorgeCF. Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease. Sleep 1993;16:318–26.
58. UchimuraN, NakajimaT, HayashK, et al. Effect of zolpidem on sleep architecture and its next-morning residual effect in insomniac patients: a randomized crossover comparative study with brotizolam. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:22–9.
59. ScharfMB, MaylebenDW, KaffemanM, KrallR, OchsR. Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry 1991;52:77–83.
60. KummerJ, GuendelL, LindenJ, et al. Long-term polysomnographic study of the efficacy and safety of zolpidem in elderly psychiatric in-patients with insomnia. J Int Med Res 1993;21:171–84.
61. WalshJK, SoubraneC, RothT. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry 2008;16:44–57.
62. KannoO, SasakiT, WatanabeH, et al. Comparison of the effects of zolpidem and triazolam on nocturnal sleep and sleep latency in the morning: a cross-over study in healthy young volunteers. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:897–910.
63. DaviesMNewellJG, DerryJMC, MartinIL, DunnSMJ. Characterization of the interaction of zopiclone with γ-aminobutyric acid type A receptor. Mol Pharmacol 2000;58:756–62.
64. MouretJ, RuelD, MaillardF, BianchiM. Zopiclone versus triazolam in insomniac geriatric patients: a specific increase in delta sleep with zopiclone. Int Clin Psychopharmacol 1990;5(Suppl 2):47–55.
65. SivertsenB, OmvikS, PallesenS, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA 2006;295:2851–8.
66. McCallWV, ErmanM, KrystalAD, et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006;22:1633–42.
67. HemmeterU, MüllerM, BischofR, AnnenB, Holsboer-TrachslerE. Effect of zopiclone and temazepam on sleep EEG parameters, psychomotor and memory functions in healthy elderly volunteers. Psychopharmacology 2000;147:384–96.
68. RoehrsT, KribbsN, ZorickF, RothT. Hypnotic residual effects of benzodiazepines with repeated administration. Sleep 1986;9:309–16.
69. DijkDJ, BeersmaDG, DaanS, van den HoofdakkerRH. Effects of seganserin, a 5-HT2 antagonist, and temazepam on human sleep stages and EEG power spectra. Eur J Pharmacol 1989;171:207–18.
70. ParrinoL, TerzanoMG. Polysomnographic effects of hypnotic drugs: a review. Psychopharmacology 1996;126:1–16.
71. TibergeM, CalvetU, KhayiN, DelahayeC, ArbusL. Comparison of the effects of zopiclone and triazolam on the sleep of normal subjects. Encephale 1988;14:319–24.
72. BilliardM, BessetA, de LustracC, BrissaudL, CadilhacJ. Effects of zopiclone on sleep, daytime somnolence and nocturnal and daytime performance in healthy volunteers. Neurophysiol Clin 1989;19:131–43.
73. YamaderaH, KatoM, TsukaharaY, KajimuraN, OkumaT. Relationship between the effects of a hypnotic drug, zopiclone, on polysomnography and on daytime EEGs. Neuropsychobiology 1997;35:152–5.
74. NakajimaT, SasakiT, NakagomeK, et al. Comparison of the effects of zolpidem and zopiclone on nocturnal sleep and sleep latency in the morning: a cross-over study in healthy young volunteers. Life Sci 2000;67:81–90.
75. GlykysJ, ModyI. Activation of GABAA receptors: views from outside the synaptic cleft. Neuron 2007;56:763–70.
76. CavelierP, HamannM, RossiD, MobbsP, AttwellD. Tonic excitation and inhibition of neurons: ambient transmitter sources and computational consequences. Prog Biophys Mol Biol 2005;87:3–16.
77. OrserBA. Extrasynaptic GABAA receptors are critical targets for sedative-hypnotic drugs. J Clin Sleep Med 2006;2:S12–8.
78. BrightDP, AllerMI, BrickleySG. Synaptic release generates a tonic GABA(A) receptor-mediated conductance that modulates burst precision in thalamic relay neurons. J Neurosci 2007;27:2560–9.
79. BrownN, KerbyJ, BonnertTP, WhitingPJ, WaffordKA. Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors. Br J Pharmacol 2002;136:965–74.
80. FaulhaberJ, SteigerA, LancelM. The GABAA agonist THIP produces slow wave sleep and reduces spindling activity in NREM sleep in humans. Psychopharmacology 1997;130:285–91.
81. WalshJK, DeaconS, DijkDJ, LundahlJ. The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia. Sleep 2007;30:593–602.
82. MathiasS, SteigerA, LancelM. The GABAa agonist gaboxadol improves the quality of post-nap sleep. Psychopharmacology 2001;157:299–304.
83. DeaconS, StanerL, StanerC, et al. Effect of short-term treatment with gaboxadol on sleep maintenance and initiation in patients with primary insomnia. Sleep 2007;30:281–7.
84. LundahlJ, StanerL, StanerC, LoftH, DeaconS. Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia. Psychopharmacology 2007;195:139–46.
85. LancelM, WetterTC, SteigerA, MathiasS. Effect of the GABAA agonist gaboxadol on nocturnal sleep and hormone secretion in healthy elderly subjects. Am J Physiol Endocrinol Metab 2001;281:E130–7.
86. MathiasS, ZihlJ, SteigerA, LancelM. Effect of repeated gaboxadol administration on night sleep and next-day performance in healthy elderly subjects. Psychopharmacology 2005;30:833–41.
87. MathiasS, WetterTC, SteigerA, LancelM. The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol Aging 2001;22:247–53.
88. WalshJK, RandazzoAC, FrankowskiS, et al. Dose-response effects of tiagabine on the sleep of older adults. Sleep 2005;28:673–6.
89. RothT, WrightKP Jr, WalshJ. Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep 2006;29:335–41.
90. WalshJK, ZammitG, SchweitzerPK, OndrasikJ, RothT. Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia. Sleep Med 2006;7:155–61.
91. RothT, SeidenD, Wang-WeigandS, ZhangJ. A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007;23:1005–14.
92. ErmanM, SeidenD, ZammitG, SainatiS, ZhangJ. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17–24.
93. ZammitG, ErmanM, Wang-WeigandS, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007;3:495–504.
94. McCarleyRW. REM sleep and depression: common neurobiological control mechanisms. Am J Psychiatry 1982;139:565–570.
95. StanerL, LuthringerR, MacherJP. Effects of antidepressant drugs on sleep EEG in patients with major depression. Mechanisms and therapeutic implications. CNS Drugs 1999;11:49–60.
96. BuysseDJ, Reynolds IIICF, HochCC, et al. Longitudinal effects of nortriptyline on EEG sleep and the likelihood of recurrence in elderly depressed patients. Neuropsychopharmacology 1996;14:243–52.
97. ReynoldsCF III, BuysseDJ, BrunnerD, et al. Maintenance nortriptyline effects on electroencephalographic sleep in elderly patients with recurrent major depression: double-blind, placebo- and plasma-level-controlled evaluation. Biol Psychiatry 1997;42:560–7.
98. KupferDJ, EhlersCL, FranckE, et al. Persistent effects of antidepressants: EEG sleep studies in depressed patients during maintenance treatment. Biol Psychiatry 1994;35:781–93.
99. MontgomeryI, OswaldI, MorganK, AdamK. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol 1983;16:139–44.
100. MouretJ, LemoineP, MinuitMP, et al. Effects of trazodone on the sleep of depressed subjects – a polygraphic study. Psychopharmacology 1988;95:S37–S43.
101. ScharfMB, SachaisBA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry 1990;51(Suppl.):13–17.
102. WareJC, RoseFV, McBrayerRH. The acute effects of nefazodone, trazodone and buspirone on sleep and sleep-related penile tumescence in normal subjects. Sleep 1994;17:544–50.
103. WolfR, DykierekP, GattazWF, et al. Differential effects of trimipramine and fluoxetine on sleep in geriatric depression. Pharmacopsychiatry 2001;34:60–5.
104. WiegandM, BergerM, ZulleyJ, von ZerssenD. The effect of trimipramine on sleep in patients with major depressive disorder. Pharmacopsychiatry 1986;19:198–9.
105. WareJC, BrownFW, MooradPJ Jr, PittartJT, CobartB. Effects on sleep: a double-blind study comparing trimipramine to imipramine in depressed insomniac patients. Sleep 1989;12:537–49.
106. KerkhofsM, RielaertC, De MartelaerV, et al. Fluoxetine in major depression: efficacy, safety and effects on sleep EEG variables. Int Clin Psychopharmacol 1990;5:253–60
107. SaletuB, FreyR, KrupkaM, et al. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 1991;14:439–47.
108. TrivediMH, RushAJ, ArmitageR, et al. Effects of fluoxetine on the polysomnogram in outpatients with major depression. Neuropsychopharmacology 1999;20:447–59.
109. SiegelJM. REM sleep. In KrygerMH, RothT, DementWC, eds. Principles and Practice of Sleep Medicine, 4th ed. Philadelphia: Elsevier Saunders; 2005: pp. 120–35.
110. BartusRT, DeanRL 3rd, BeerB, LippaAS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408–14.
111. PetitD, MontplaisirJ, BoeveBF. Alzheimer’s disease and other dementia. In KrygerMH, RothT, DementWC, eds. Principles and Practice of Sleep Medicine, 4th ed. Philadelphia: Elsevier Saunders; 2005: pp. 853–62.
112. SchredlM, WeberB, BrausD, et al. The effect of rivastigmine on sleep in elderly healthy subjects. Exp Gerontol 2000;35:243–9.
113. SchredlM, HornungO, RegenF, et al. The effect of donepezil on sleep in elderly, healthy persons: a double-blind placebo-controlled study. Pharmacopsychiatry 2006;39:205–8.
114. HornungOP, RegenF, Danker-HopfeH, SchredlM, HeuserI. The relationship between REM sleep and memory consolidation in old age and effects of cholinergic medication. Biol Psychiatry 2007;61:750–7.
115. SitaramN, MendelsonWB, WyattRJ, GillinJC. The time-dependent induction of REM sleep and arousal by physostigmine infusion during normal human sleep. Brain Res 1977;122:562–7.
116. Holsboer-TrachslerE, HatzingerM, StohlerR, et al. Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man. Neuropsychopharmacology 1993;8:87–92.
117. RiemannD, GannH, DressingH, MüllerWE, AldenhoffJB. Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep. Psychiatry Res 1994;51:253–67.
118. KanbayashiT, SugiyamaT, AizawaR, et al. Effects of donepezil (Aricept) on the rapid eye movement sleep of normal subjects. Psychiatry Clin Neurosci 2002;56:307–8.
119. NissenC, NofzingerEA, FeigeB, et al. Differential effects of the muscarinic M1 receptor agonist RS-86 and the acetylcholine-esterase inhibitor donepezil on REM sleep regulation in healthy volunteers. Neuropsychopharmacology 2006;31:1294–300.
120. MizunoS, KamedaA, InagakiT, HoriguchiJ. Effects of donepezil on Alzheimer’s disease: the relationship between cognitive function and rapid eye movement sleep. Psychiatry Clin Neurosci 2004;58:660–5.
121. Moraes WdosS, PoyaresDR, GuilleminaultC, et al. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. Sleep 2006;29:199–205.
122. RaoU, LutchmansinghP, PolandRE. Age-related effects of scopolamine on REM sleep regulation in normal control subjects: relationship to sleep abnormalities in depression. Neuropsychopharmacology 1999;21:723–30.
123. PerlisML, SmithMT, OrffHJ, et al. The effects of an orally administered cholinergic agonist on REM sleep in major depression. Biol Psychiatry 2002;51:457–62.
124. SchredlM, WeberB, LeinsML, HeuserI. Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons. Exp Gerontol 2001;36:353–61.
125. TononiG, CirelliC. Sleep function and synaptic homeostasis. Sleep Med Rev 2006;10:49–62.

References

1. VermeerenA. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004;18(5):297–328.
2 National Institutes of Health. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13–15, 2005. Sleep 2005;28(9):1049–57.
3. BeckA. Cognitive Therapy of Depression. New York: Guilford Press; 1987.
4. ButlerAC, ChapmanJE, FormanEM, BeckAT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev 2006;26(1):17–31.
5. BorbelyAA. A two process model of sleep regulation. Human Neurobiol 1982;1:195–204.
6. SpielmanA, CarusoL, GlovinskyP. A behavioral perspective on insomnia treatment. Psychiatr Clin North Am 1987;10:541–53.
7. MorgenthalerT, AlessiC, FriedmanL. et al. Standards of Practice Committee & American Academy of Sleep Medicine 2007 – Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. Sleep 30(4):519–29.
8. StepanskiEJ, WyattJK. Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev 2003;7(3):215–25.
9. Ancoli-IsraelS, MartinJL. Insomnia and daytime napping in older adults. J Clin Sleep Med: Official Publication of the American Academy of Sleep Medicine 2006;2(3):333–42.
10. CheekRE, ShaverJL, LentzMJ. Variations in sleep hygiene practices of women with and without insomnia. Res Nurs Health 2004;27(4):225–36.
11. GilbertSS, van den HeuvelCJ, FergusonSA, DawsonD. Thermoregulation as a sleep signalling system. Sleep Med Rev 2004;8(2):81–93.
12. National Sleep Foundation/WB&A Market Research. Sleep in American Survey. Washington, DC: National Sleep Foundation; 2005.
13. YoungstedtSD. Effects of exercise on sleep. Clin Sports Med 2005;24(2):355–65, xi.
14. Ancoli-IsraelS, KlauberMR, JonesDW, et al. Variations in circadian rhythms of activity, sleep, and light exposure related to dementia in nursing-home patients. Sleep 1997;20:18–23.
15. McCraeCS, RoweMA, DautovichND, et al. Sleep hygiene practices in two community dwelling samples of older adults. Sleep 2006;29(12):1551–60.
16. BootzinRR, NicassioPM. Behavioral treatments for insomnia. In HersenM, EislerRM, MillerPM, eds. Progress in Behavior Modification, Vol. 6. New York: Academic Press; 1978: pp. 1–45.
17. BuysseDJ, MonkTH, ReynoldsCF 3rd, et al. Patterns of sleep episodes in young and elderly adults during a 36-hour constant routine. Sleep 1993;16(7):632–7.
18. LichsteinKL, RiedelBW, WilsonNM, LesterKW, AguillardRN. Relaxation and sleep compression for late-life insomnia: a placebo-controlled trial. J Consult Clin Psychol 2001;69(2):227–39.
19. HarveyAG, SharpleyAL, ReeMJ, StinsonK, ClarkDM. An open trial of cognitive therapy for chronic insomnia. Behav Res Ther 2007;45(10):2491–501.
20. HarveyAG, TangNK, BrowningL. Cognitive approaches to insomnia. Clin Psychol Rev 2005;25(5):593–611.
21. KripkeD, GarfinkelL, WingardD, KlauberM, MarlerM. Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 2002;59:137–8.
22. MorinC, StoneJ, TrinkleD, MercerJ, RemsbergS. Dysfunctional beliefs and attitudes about sleep among older adults with and without insomnia complaints. Psychol Aging 1993;8(3):463–7.
23. ReeMJ, HarveyAG. Behavioural experiments in chronic insomnia. In Bennet-LevyJ, ButlerG, FennelMJV, et al., eds. Oxford Guide to Behavioural Experiments in Cognitive Therapy. Oxford: Oxford University Press; 2004: pp. 287–308.
24. LundhL. The role of acceptance and mindfulness in the treatment of insomnia. J Cog Psychother: An International Quarterly 2005;19(1):29–39.
25. Kabat-Zinn, J. Wherever You Go There You Are. New York: Hyperion; 1994
26. CarlsonLE, GarlandSN. Impact of mindfulness-based stress reduction (MBSR) on sleep, mood, stress and fatigue symptoms in cancer outpatients. J Behav Med 2005;12(4):278–85.
27. SmithJE, RichardsonJ, HoffmanC, PilkingtonK. Mindfulness-based stress reduction as supportive therapy in cancer care: systematic review. J Adv Nurs 2005;52(3):315–27.
28. MasonLI, AlexanderCN, TravisFT, et al. Electrophysiological correlates of higher states of consciousness during sleep in long-term practitioners of the Transcendental Meditation program. Sleep 1997;20(2):102–10.
29. BastienCH, MorinCM, OuelletMC, BlaisFC, BouchardS. Cognitive-behavioral therapy for insomnia: comparison of individual therapy, group therapy, and telephone consultations. J Consult Clin Psychol 2004;72(4):653–9.
30. MimeaultV, MorinCM. Self-help treatment for insomnia: bibliotherapy with and without professional guidance. J Consult Clin Psychol 1999;67(4):511–9.
31. StromL, PetterssonR, AnderssonG. Internet-based treatment for insomnia: a controlled evaluation. J Consult Clin Psychol 2004;72(1):113–20.
32. MorinCM, ColecchiC, StoneJ, SoodR, BrinkD. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999;281:991–9.
33. MontgomeryP, DennisJ. Cognitive behavioural interventions for sleep problems in adults aged 60+. Coch Database System Rev (Online) 2003;1(1):CD003161.
34. SmithMT, HuangMI, ManberR. Cognitive behavior therapy for chronic insomnia occurring within the context of medical and psychiatric disorders. Clin Psychol Rev 2005;25(5):559–92.
35. McCurrySM, LogsdonRG, TeriL, VitielloMV. Evidence-based psychological treatments for insomnia in older adults. Psychol Aging 2007;22(1):18–27.
36. McCurrySM, GibbonsLE, LogsdonRG, VitielloMV, TeriL. Nighttime insomnia treatment and education for Alzheimer’s disease: a randomized, controlled trial. J Am Geriatr Soc 2005;53(5):793–802.
37. MendelsonWB. Combining pharmacologic and nonpharmacologic therapies for insomnia. J Clin Psychiatry 2007;68(Suppl. 5):19–23.
38. SoeffingJP, LichsteinKL, NauSD, et al. Psychological treatment of insomnia in hypnotic-dependant older adults. Sleep Med 2008;9(2):165–71.
39. PerlisML, SmithMT, OrffH, et al. The effects of modafinil and cognitive behavior therapy on sleep continuity in patients with primary insomnia. Sleep 2004;27(4):715–25.
40. MorinCM, CulbertJP, SchwartzMS. Non-pharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 1994;151:1172–80.
41. MurtaghDR, GreenwoodKM. Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol 1995;63:79–89.
42. SmithMT, PerlisML, ParkA, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002;159(1):5–11.
43. SivertsenB, OmvikS, PallesenS, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA 2006;295(24):2851–8.
44. MorgenthalerT, KramerM, AlessiC, et al. & American Academy of Sleep Medicine. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine report, Sleep 2006;29(11):1415–9.

References

1. MorinCM, BootzinRR, BuysseDJ, et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998–2004). Sleep 2006;29(11):1398–414.
2. Ancoli-IsraelS. Insomnia in the elderly: a review for the primary care practitioners. Sleep 2000;23:S23–S30.
3. FoleyDJ, MonjanAA, BrownSL, et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 1995;18:425–32.
4. PetitL, AzadN, ByszewskiA, SarazanF, Power, B. Non-pharmacological management of primary and secondary insomnia among older people: review of assessment tools and treatments. Age and Ageing 2003;32:19–25.
5. Ancoli-IsraelS, AyalonL. Diagnosis and treatment of sleep disorders in older adults. Am J Geriatr Psychiatry 2006;14(2):95–103.
6. LichsteinKL. Secondary insomnia. In LichsteinKL, Morin CM, eds. Treatment of Late-life Insomnia. Thousand Oaks: Sage Publications; 2000; pp. 297–319.
7. National Institutes of Health State of the Science Conference Statement. Manifestations and management of chronic insomnia in adults, June 13–15, 2005. Sleep 2005;28(9).
8. BreslauN, RothT, RosenthalL, Andreski, P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411–18.
9. MorinCM, BlaisF, SavardJ. Are changes in beliefs and attitudes about sleep related to sleep improvements in the treatment of insomnia?Behav Res Ther 2002;40;741–52.
10. KatzDA, McHorneyCA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med 1998;158:1099–107.
11. StollerMK. Economic effects of insomnia. Clin Ther 1994;16(5):873–97
12. IrwinMR, ColeJC, NicassioPM. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychol 2006;25(1):3–14.
13. MorinCM, ColecchiCA, StoneJ, SoodR, BrinkD. Behavioral and pharmacological therapies for late-life insomnia: a randomized clinical trial. J Am Med Assoc 1999;281:991–9.
14. McCluskyHY, MilbyJB, SwitzerPK, WilliamsV, WootenV. Efficacy of behavioral versus triazolam treatment in persistent sleep-onset insomnia. Am J Psychiatry 1991;148(1):121–6.
15. MorinCM, WootenV. Psychological and pharmacological approaches to treating insomnia: critical issues in assessing their separate and combined effects. Clin Psychol Rev 1996;16(6):521–42.
16. SmithMT, HuangMI, ManberR. Cognitive behavior therapy for chronic insomnia occurring within the context of medical and psychiatric disorders. Clin Psychol Rev 2005;25(5):559–92.
17. BastienCH, MorinCM, OuelletMC. Cognitive-behavioral therapy for insomnia: comparison of individual therapy, group therapy, and telephone consultations. J Consult Clin Psychol 2004;72(4): 653–9.
18. BaillargeonL, DemersM, GrégoireJP, PépinM. Study on insomnia treatment by family physicians. Can Fam Physician 1996;42:426–32.
19. AlpersonJ, BiglanA. Self-administered treatment of sleep onset insomnia and the importance of age. Behav Ther 1979;10(3):347–56.
20. RiedelBW, LichsteinKL, DwyerWO. Sleep compression and sleep education for older insomniacs: self-help versus therapist guidance. Psychol Aging 1995; 10(1):54–63.
21. MorinCM, Beaulieu-BonneauS, LeBlancM, SavardJ. Self-help treatment for insomnia: a randomized controlled trial. Sleep 2005;28(10):1319–27.
22. MimeaultV, MorinCM. Self-help treatment for insomnia: bibliotherapy with and without professional guidance. J Consult Clin Psychol 1999;67(4):511–19.
23. MorawetzD. Behavioral self-help treatment for insomnia: a controlled evaluation. Behav Ther 1989;20(3):365–79.
24. RybarczykB, LopezM, SchelbleK. Home-based video CBT for comorbid geriatric insomnia: a pilot study using secondary data analyses. Behav Sleep Med 2005;3(3):158–75.
25. StrömL, PetterssonP, AnderssonG. Internet-based treatment for insomnia: a controlled evaluation. J Consult Clin Psychol 2004;72(1):113–20.
26. GlasgowRE, RosenGM, Behavioral bibliotherapy: a review of self-help behavior therapy manuals. Psychol Bull 1978;85(1):1–23.
27. ScoginF, BynuJ, StephensG. Efficacy of self-administered treatment programs: Meta-analytic review. Prof Psychol Res Pr 1990;21(1):42–7.
28. van BoeijenCA, van BalkomAJ, van OppenP, et al. Efficacy of self-help manuals for anxiety disorders in primary care: a systematic review. Fam Pract 2005; 22(2):192–6.
29. AnderssonG, BergströmJ, CarlbringP, LindeforsN. The use of the Internet in the treatment of anxiety disorders. Curr Opin Psychiatry 2005;18(1):73–7.
30. FloydM, ScoginF, McKendree-SmithNL, FloydDL, RokkePD. Cognitive therapy for depression: a comparison of individual psychotherapy and bibliotherapy for depressed older adults. Behav Modif 2004;28(2):297–318.
31. CuijpersP. Bibliotherapy in unipolar depression: a meta-analysis. J Behav Ther Exp Psychiatry 1997;28(2):139–47.
32. StefanoSC, BacaltchukJ, BlaySL, HayP. Self-help treatments for disorders of recurrent binge eating: a systematic review. Acta Psychiatr Scand Jun 2006;113(6):452–9.
33. ApodacaTR, MillerWR. A meta-analysis of the effectiveness of bibliotherapy for alcohol problems. J Clin Psychol 2003;59(3):289–304.
34. RiperH, KramerJ, SmitF, et al. Web-based self-help for problem drinkers: a pragmatic randomized trial. Addiction 2008;103(2):218–27.
35. CurrySJ, LudmanEJ, McClureJ. Self-administered treatment for smoking cessation. J Clin Psychol 2003;59(3):305–19.
36. KillenJD, FortmannSP, DavisL, VaradyA. Nicotine patch and self-help video for cigarette smoking cessation. J Consult Clin Psychol 1997;65(4):663–72.
37. BuenaverLF, McGuireL, HaythornthwaiteJA. Cognitive-behavioral self-help for chronic pain. J Clin Psychol 2006;62(11):1389–96.
38. StrömL, PetterssonR, AnderssonG. A controlled trial of self-help treatment of recurrent headache conducted via the Internet. J Consult Clin Psychol 2000;68(4):722–7.
39. KaldoV, CarsS, RahnertM, LarsenHC, AnderssonG. Use of a self-help book with weekly therapist contact to reduce tinnitus distress: a randomized controlled trial. J Psychosom Res 2007;63(2):195–202.
40. Pezzot-PearceTD, LeBowMD, PearceJW. Increasing cost-effectiveness in obesity treatment through use of self-help behavioral manuals and decreased therapist contact. J Consult Clin Psychol 1982;50(3):448–9.
41. BennettP, PhelpsC, BrainK, HoodK, GrayJ. A randomized controlled trial of a brief self-help coping intervention designed to reduce distress when awaiting genetic risk information. J Psychosom Res 2007;63(1):59–64.
42. MainsJA, ScoginFR. The effectiveness of self-administered treatments: a practice-friendly review of the research. J Clin Psychol 2003;59(2):237–46.
43. GouldRA, ClumGA. A meta-analysis of self-help treatment approaches. Clin Psychol Rev 1993;13(2):169–86.
44. BootzinRR, Self management techniques for controlling insomnia. In FranksCM, ed. Behavior Therapy: Techniques, Principles, and Patient Aids. New York: Biomonitoring Applications, Inc; 1976 (audiotape).
45. RybarczykB, LopezM, BensonR, AlstenC, StepanskiE. Efficacy of two behavioral treatment programs for comorbid geriatric insomnia. Psychol Aging 2002;17(2):288–98.
46. RybarczykB, LopezM, SchelbleK, StepanskiE. Home-based video CBT for comorbid geriatric insomnia: a pilot study using secondary data analyses. Behav Sleep Med 2005;3(3):158–75.
47. RybarczykB, DeMarcoG, DeLaCruzM, LapidosS. Comparing mind-body wellness interventions for older adults with chronic illness: classroom versus home instruction. Behav Med 1999;24(4):181–90.
48. LichsteinKL, WilsonNM, JohnsonCT. Psychological treatment of secondary insomnia. Psychol Aging 2000;15:232–40.
49. MurrayK, Pombo-CarrilMG, Bara-CarrilN. Factors determining uptake of a CD-ROM-based CBT self-help treatment for bulimia: patient characteristics and subjective appraisals of self-help treatment. Eur Eat Disord Rev 2003;11(3):243–60.
50. ScoginFR, HansonA, WelshD. Self-administered treatment in stepped-care models of depression treatment. J Clin Psychol 2003;59(3):341–9.
51. EdingerJD. Controversial and Unresolved Issues in the Treatment of Insomnia. Panel discussion at the meeting of the Associated Professional Sleep Societies, Chicago, 2003.
52. WilsonGT, VitousekKM, LoebKL. Stepped care treatment for eating disorders. J Consult Clin Psychol 2000;68(4):564–72.
53. SobellMB, SobellLC. Stepped care as a heuristic approach to the treatment of alcohol problems. J Consult Clin Psychol 2000;68(4):573–9.
54. NewmanMG. Recommendations for a cost-offset model of psychotherapy allocation using generalized anxiety disorder as an example. J Consult Clin Psychol 2000;63(4):549–55.
55. OttoMW, PollackMH, MakiKM. Empirically supported treatments for panic disorder: costs, benefits, and stepped care. J Consult Clin Psychol 2000;68(4):556–63.

References

1. US National Center for Complementary and Alternative Medicine (NCCAM). http://nccam.nih.gov/health/whatiscam (accessed 16 Dec 2007).
2. American Association of Retired Persons, National Center for Complementary and Alternative Medicine. Complementary and Alternative Medicine: What People 50 and Older Are Using and Discussing with Their Physicians. Washington, DC: AARP; 2007. Available at http://assets.aarp.org/rgcenter/health/cam_2007.pdf(accessed 5 Feb 2008).
3. BrunoJJ, EllisJJ. Herbal use among US elderly: 2002 National Health Interview Survey. Ann Pharmacother 2005;39:643–8.
4. CuellarNG, RogersAE, HisghmanV. Evidenced based research of complementary and alternative medicine (CAM) for sleep in the community dwelling older adult. Geriatr Nurs 2007;28:46–52.
5. PearsonNJ, JohnsonLL, NahinRL. Insomnia, trouble sleeping, and complementary and alternative medicine: Analysis of the 2002 national health interview survey data. Arch Intern Med 2006;166:1775–82.
6. http://www.naturalstandard.com (accessed 5 Jan 2008).
7. BliwiseDL, AnsariFP. Insomnia associated with valerian and melatonin usage in the 2002 National Health Interview Survey. Sleep 2007;30:881–4.
8. GooneratneNS. Complementary and alternative medicine for sleep disturbances in older adults. Clin Geriatr Med 2008;24:121–38.
9. ErnstE, PittlerMH, WiderB, BoddyK. The Desktop Guide to Complementary and Alternative Medicine. 2nd ed. Edinburgh: Mosby; 2006.
10. ErnstE, PittlerMH, WiderB, BoddyK. Oxford Handbook on Complementary Medicine. Oxford: Oxford University Press; 2008.
11. Olde-RikkertMG, RigaudAS. Melatonin in elderly patients with insomnia: a systematic review. Z Gerontol Geriatr 2001;34:491–7.
12. BrzezinskiA, VangelMG, WurtmanRJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005;9:41–50.
13. BuscemiN, VandermeerB, PandyaR, et al. Melatonin for Treatment of Sleep Disorders. Evidence Report/Technology Assessment: Number 108. AHRQ Publication Number 05-E002–1, November 2004. Rockville, MD: Agency for Healthcare Research and Quality; 2004. Available at http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1.chapter.127295(accessed 6 Mar 2008).
14. BuscemiN, VandermeerB, HootonN, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders: a meta-analysis. J Gen Intern Med 2005;20:1151–8.
15. BuscemiN, VandermeerB, HootonN, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006;332:385–93.
16. StevinsonC, ErnstE. Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Med 2000;1:91–9.
17. BentS, PadulaA, MooreD, PattersonM, MehlingW. Valerian for sleep: a systematic review and meta-analysis. Am J Med 2006;119:1005–12.
18. TaibiDM, LandisCA, PetryH, VitielloMV. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev 2007;11:209–30.
19. OxmanAD, FlottorpS, HåvelsrudK, et al. A televised, web-based randomised trial of an herbal remedy (valerian) for insomnia. PLoS ONE 2007;2:e1040.
20. Kamm-KohlAV, JansenW, BrockmannP. Moderne Baldriantherapie gegen nervöse Störungen im Senium. Med Welt 1984;35:1450–4.
21. LehrlS. Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders: results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. J Affect Disord 2004;78:101–10.
22. JacobsBP, BentS, TiceJA, BlackwellT, CummingsSR. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine (Baltimore) 2005;84:197–207.
23. CheukDKL, YeungWF, ChungKF, WongV. Acupuncture for insomnia. Coch Database Syst Rev 2007;3:CD005472.
24. ChenML, LinLC, WuSC, LinJG. The effectiveness of acupressure in improving the quality of sleep of institutionalized residents. J Gerontol 1999;54:389–94.
25. SuenLK, WongTK, LeungAW. Effectiveness of auricular therapy on sleep promotion in the elderly. Am J Chin Med 2002;30:429–49.
26. LichsteinKL, RiedelBW, WilsonNM, LesterKW, AguillardRN. Relaxation and sleep compression for late-life insomnia: a placebo-controlled trial. J Consult Clin Psychol 2001;69:227–39.
27. RybarczykB, LopezM, BensonR, AlstenC, StepanskiE. Efficacy of two behavioral treatment programs for comorbid geriatric insomnia. Psychol Aging 2002;17:288–98.
28. MorinCM, BootzinRR, BuysseDJ, et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998–2004). Sleep 2006;29:1398–414.
29. SimeitR, DeckR, Conta-MarxB. Sleep management training for cancer patients with insomnia. Support Care Cancer 2004;12:176–83.
30. StetterF, KupperS. Autogenes Training – Qualitative Meta-Analyse kontrollierter klinischer Studien und Beziehungen zur Naturheilkunde. Forsch Komplementarmed 1998;5:211–23.
31. ManjunathNK, TellesS. Influence of Yoga and Ayurveda on self-rated sleep in a geriatric population. Indian J Med Res 2005;121:683–90.
32. BowerJE, WooleryA, SternliebB, GaretD. Yoga for cancer patients and survivors. Cancer Control 2005;12:165–71.
33. LiF, FisherKJ, HarmerP, et al. Tai chi and self-rated quality of sleep and daytime sleepiness in older adults: a randomized controlled trial. J Am Geriatr Soc 2004;52:892–900.
34. LaiHL, GoodM. Music improves sleep quality in older adults. J Adv Nurs 2005;49:234–44.

References

1. TakahashiM. The role of prescribed napping in sleep medicine. Sleep Med Rev 2003;7(3):227–35.
2. TairaK, TanakaH, ArakawaM, et al. Sleep health and lifestyle of elderly people in Ogimi, a village of longevity. Psychiatry Clin Neurosci 2002;56(3):243–4.
3. HaysJC, BlazerDG, FoleyDJ. Risk of napping: excessive daytime sleepiness and mortality in an older community population. J Am Geriatr Soc 1996;44(6):693–8.
4. StepanskiEJ, WyattJK. Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev 2003;7(3):215–25.
5. FoleyDJ, VitielloMV, BliwiseDL, et al. Frequent napping is associated with excessive daytime sleepiness, depression, pain, and nocturia in older adults: findings from the National Sleep Foundation ‘2003 Sleep in America’ Poll. Am J Geriatr Psychiatry 2007;15(4):344–50.
6. BursztynM, StessmanJ. The siesta and mortality: twelve years of prospective observations in 70-year-olds. Sleep 2005;28(3):345–7.
7. OhayonMM, VecchieriniMF. Daytime sleepiness and cognitive impairment in the elderly population. Arch Intern Med 2002;162(2):201–8.
8. EvansFJ, CookMR, CohenHD, OrneEC, OrneMT. Appetitive and replacement naps: EEG and behavior. Science 1977;197(4304):687–9.
9. BuysseDJ, ReynoldsCD, MonkTH, et al. Quantification of subjective sleep quality in healthy elderly men and women using the Pittsburgh Sleep Quality Index (PSQI). Sleep 1991;14(4):331–8.
10. FoleyD, MonjanA, BroenS, et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 1995;18(6):425–32.
11. OhayonMM, VecchieriniMF. Normative sleep data, cognitive function and daily living activities in older adults in the community. Sleep 2005;28(8):981–9.
12. EspirituJR. Aging-related sleep changes. Clin Geriatr Med 2008;24(1):1–14, v.
13. HochCC, DewMA, ReynoldsCF 3rd, et al. A longitudinal study of laboratory- and diary-based sleep measures in healthy “old old” and “young old” volunteers. Sleep 1994;17(6):489–96.
14. CampbellS, DawsonD, AndersonM. Alleviation of sleep maintenance insomnia with timed exposure to bright light. J Am Geriatr Soc 1993;41:829–36.
15. WebbWB, AberWR. Relationships between sleep and retirement-nonretirement status. Int J Aging Hum Dev 1984;20(1):13–19.
16. CampbellSS, MurphyPJ. The nature of spontaneous sleep across adulthood. J Sleep Res 2007;16(1):24–32.
17. BuysseDJ, BrowmanKE, MonkTH, et al. Napping and 24-hour sleep/wake patterns in healthy elderly and young adults. J Am Geriatr Soc 1992;40(8):779–86.
18. DementWC, MilesLE, CarskadonMA. “White paper” on sleep and aging. J Am Geriatr Soc 1982;30(1):25–50.
19. DijkDJ, DuffyJF, CzeislerCA. Contribution of circadian physiology and sleep homeostasis to age-related changes in human sleep. Chronobiol Int 2000;17(3):285–311.
20. WebbWB. Age-related changes in sleep. Clin Geriatr Med 1989;5(2):275–87.
21. GeislerP, TracikF, CronleinT, et al. The influence of age and sex on sleep latency in the MSLT-30 – a normative study. Sleep 2006;29(5):687–92.
22. LavieP. Ultrashort sleep-waking schedule. III: ‘gates’ and ‘forbidden zones’ for sleep. Electroencephalogr Clin Neurophysiol 1986;63(5):414–25.
23. CampbellSS, ZulleyJ. Ultradian components of human sleep/wake patterns during disentrainment. In LavieP, ed. Ultradian Rhythms in Physiology and Behavior. Berlin: Springer-Verlag; 1985: pp. 234–55.
24. HayashiM, WatanabeM, HoriT. The effects of a 20 min nap in the mid-afternoon on mood, performance and EEG activity. Clin Neurophysiol 1999;110(2):272–9.
25. DingesDF. Adult napping and its effects on ability to function. In StampiC, ed. Why We Nap: Evolution, Chronobiology, and Functions of Polyphasic and Ultrashort Sleep. Boston: Birkhauser; 1992; pp. 118–34.
26. TaubJM. Effects of habitual variations in napping on psychomotor performance, memory and subjective states. Int J Neurosci 1979;9(2):97–112.
27. TietzelAJ, LackLC. The short-term benefits of brief and long naps following nocturnal sleep restriction. Sleep 2001;24(3):293–300.
28. VgontzasAN, PejovicS, ZoumakisE, et al. Daytime napping after a night of sleep loss decreases sleepiness, improves performance, and causes beneficial changes in cortisol and interleukin-6 secretion. Am J Physiol Endocrinol Metab 2007;292(1):E253–61.
29. TamakiM, ShirotaA, HayashiM, HoriT. Restorative effects of a short afternoon nap (<30 min) in the elderly on subjective mood, performance and EEG activity. Sleep Res Online 2000;3(3):131–9.
30. TanakaH, TairaK, ArakawaM, et al. Effects of short nap and exercise on elderly people having difficulty in sleeping. Psychiatry Clin Neurosci 2001;55(3):173–4.
31. TanakaH, TairaK, ArakawaM, et al. Short naps and exercise improve sleep quality and mental health in the elderly. Psychiatry Clin Neurosci 2002;56(3):233–4.
32. CampbellSS, MurphyPJ, StaubleTN. Effects of a nap on nighttime sleep and waking function in older subjects. J Am Geriatr Soc 2005;53(1):48–53.
33. MonkTH, BuysseDJ, CarrierJ, et al. Effects of afternoon “siesta” naps on sleep, alertness, performance, and circadian rhythms in the elderly. Sleep 2001;24(6):680–7.
34. TamakiM, ShirotaA, TanakaH, HayashiM, HoriT. Effects of a daytime nap in the aged. Psychiatry Clin Neurosci 1999;53(2):273–5.
35. MetzME, BunnellDE. Napping and sleep disturbances in the elderly. Fam Pract Res J 1990;10(1):47–56.
36. DriscollHC, SerodyL, PatrickS, et al. Sleeping well, aging well: a descriptive and cross-sectional study of sleep in “successful agers” 75 and older. Am J Geriatr Psychiatry 2008;16(1):74–82.
37. PilcherJJ, MichalowskiKR, CarriganRD. The prevalence of daytime napping and its relationship to nighttime sleep. Behav Med 2001;27(2):71–6.
38. WilliamsR, KaracanI, HurschC. Electroencephalography of Human Sleep: Clinical Applications. New York: John Wiley & Sons; 1970.
39. DingesDF, BroughtonRJ, eds. Sleep and Alertness: Chronobiological, Behavioral and Medical Aspects of Napping. New York: Raven Press; 1989.
40. NaitohP, KellyT, BabkoffH. Sleep inertia: best time not to wake up?Chronobiol Int 1993;10(2):109–18.
41. BrooksA, LackL. A brief afternoon nap following nocturnal sleep restriction: which nap duration is most recuperative?Sleep 2006;29(6):831–40.
42. DhandR, SohalH. Good sleep, bad sleep! The role of daytime naps in healthy adults. Curr Opin Pulm Med 2006;12(6):379–82.
43. CamposH, SilesX. Siesta and the risk of coronary heart disease: results from a population-based, case-control study in Costa Rica. Int J Epidemiol 2000;29(3):429–37.
44. NaskaA, OikonomouE, TrichopoulouA, PsaltopoulouT, TrichopoulosD. Siesta in healthy adults and coronary mortality in the general population. Arch Intern Med 2007;167(3):296–301.
45. TrichopoulosD, TzonouA, ChristopoulosC, HavatzoglouS, TrichopoulouA. Does a siesta protect from coronary heart disease?Lancet 1987;2(8553):269–70.
46. MullerJE. Circadian variation and triggering of acute coronary events. Am Heart J 1999;137(4 Pt 2):S1–S8.
47. MitlerMM, HajdukovicRM, ShaforR, HahnPM, KripkeDF. When people die: cause of death versus time of death. Am J Med 1987;82(2):266–74.
48. ElliottWJ. Circadian variation in the timing of stroke onset: a meta-analysis. Stroke 1998;29(5):992–6.
49. WhiteWB. Importance of aggressive blood pressure lowering when it may matter most. Am J Cardiol 2007;100(3A):10J–16J.
50. SmolenskyMH, HermidaRC, CastriottaRJ, PortaluppiF. Role of sleep-wake cycle on blood pressure circadian rhythms and hypertension. Sleep Med 2007;8(6):668–80.
51. SomersVK, DykenME, MarkAL, AbboudFM. Sympathetic-nerve activity during sleep in normal subjects. N Engl J Med 1993;328(5):303–7.
52. TrinderJ, AllenN, KleimanJ, et al. On the nature of cardiovascular activation at an arousal from sleep. Sleep 2003;26(5):543–51.
53. NalivaikoE, CatchesidePG, AdamsA, et al. Cardiac changes during arousals from non-REM sleep in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2007;292(3):R1320–7.
54. Lopez-JimenezF, Sert KuniyoshiFH, GamiA, SomersVK. Obstructive sleep apnea: implications for cardiac and vascular disease. Chest 2008;133(3):793–804.
55. BursztynM, MeklerJ, Ben-Ishay. The siesta and blood pressure: different hemodynamics of the morning and afternoon awakening. Am J Hyperten 2005;8(4, Part 2):164A.
56. HaimovI, LavieP. Circadian characteristics of sleep propensity function in healthy elderly: a comparison with young adults. Sleep 1997;20(4):294–300.
57. YoonIY, KripkeDF, ElliottJA, LangerRD. Naps and circadian rhythms in postmenopausal women. J Gerontol A Biol Sci Med Sci 2004;59(8):844–8.

References

1. ChessonJ, AndrewL, LittnerM, et al. Practice parameters for the use of light therapy in the treatment of sleep disorders. Sleep 1999;22(5):641–60.
2. MontgomeryP, DennisJ. Bright light therapy for sleep problems in adults aged 60+. Coch Database Syst Rev 2002(2):CD003403.
3. CajochenC. Alerting effects of light. Sleep Med Rev 2007;11(6):453–64.
4. MurphyPJ, CampbellSS. Enhanced performance in elderly subjects following bright light treatment of sleep maintenance insomnia. J Sleep Res 1996;5(3):165–72.
5. BrainardGC, HanifinJP. Photons, clocks, and consciousness. J Biol Rhythms 2005;20(4):314–25.
6. FigueiroMG, BulloughJD, ParsonsRH, ReaMS. Preliminary evidence for spectral opponency in the suppression of melatonin by light in humans. Neuroreport 2004;15(2):313–6.
7. DaceyDM, LiaoHW, PetersonBB, et al. Melanopsin-expressing ganglion cells in primate retina signal colour and irradiance and project to the LGN. Nature 2005;433(7027):749–54.
8. HannibalJ, HinderssonP, OstergaardJ, et al. Melanopsin is expressed in PACAP-containing retinal ganglion cells of the human retinohypothalamic tract. Invest Ophthalmol Vis Sci 2004;45(11):4202–9.
9. PandaS, NayakSK, CampoB, et al. Illumination of the melanopsin signaling pathway. Science 2005;307(5709):600–4.
10. BrainardGC, HanifinJP, GreesonJM, et al. Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. J Neurosci 2001;21(16):6405–12.
11. LockleySW, BrainardGC, CzeislerCA. High sensitivity of the human circadian melatonin rhythm to resetting by short wavelength light. J Clin Endocrinol Metab 2003;88(9):4502–5.
12. WarmanVL, DijkDJ, WarmanGR, ArendtJ, SkeneDJ. Phase advancing human circadian rhythms with short wavelength light. Neurosci Lett 2003;342(1–2):37–40.
13. KaidaK, TakahashiM, HarataniT, et al. Indoor exposure to natural bright light prevents afternoon sleepiness. Sleep 2006;29(4):462–9.
14. DuffyJF, WrightKP Jr. Entrainment of the human circadian system by light. J Biol Rhythms 2005;20(4):326–38.
15. Van SomerenEJ. Circadian and sleep disturbances in the elderly. Exp Gerontol 2000;35:1229–37.
16. Van SomerenEJ, RiemersmaRF, SwaabDF. Functional plasticity of the circadian timing system in old age: light exposure. Progr Brain Res 2002;138:205–31.
17. BenloucifS, GreenK, L’Hermite-BaleriauxM, et al. Responsiveness of the aging circadian clock to light. Neurobiol Aging 2006;27(12):1870–9.
18. KlermanEB, DuffyJF, DijkDJ, CzeislerCA. Circadian phase resetting in older people by ocular bright light exposure. J Investig Med 2001;49(1):30–40.
19. KripkeDF, ElliottJA, YoungstedtSD, RexKM. Circadian phase response curves to light in older and young women and men. J Circadian Rhythms 2007;5:4.
20. AlgverePV, MarshallJ, SeregardS. Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol Scand 2006;84(1):4–15.
21. CharmanWN. Age, lens transmittance, and the possible effects of light on melatonin suppression. Ophthalmic Physiol Opt 2003;23(2):181–7.
22. RosenbloomAAJ, ed. Rosenbloom & Morgan’s Vision and Aging. St, Louis: Butterworth-Heinemann; 2007.
23. National Eye Institute. Summary of eye disease prevalence data. Updated Dec 2006. (cited 29 Mar 2008). Available at: http://www.nei.nih.gov/eyedata/pbd_tables.asp
24. KripkeD. The uses of bright light in an office practice. In PocentaSJ, MitlerMM, eds. Sleep Disorders: Diagnosis and Treatment. Totowa, New Jersey: Humana Press; 1998: pp. 53–74.
25. SavidesTJ, MessinS, SengerC, KripkeDF. Natural light exposure of young adults. Physiol Behav 1986;38(4):571–4.
26. EspirituRC, KripkeDF, Ancoli-IsraelS, et al. Low illumination experienced by San Diego adults: association with atypical depressive symptoms. Biol Psychiatry 1994;35(6):403–7.
27. MelinA, WilskeJ, RingertzH, SaafM. Seasonal variations in serum levels of 25-hydroxyvitamin D and parathyroid hormone but no detectable change in femoral neck bone density in an older population with regular outdoor exposure. J Am Geriatr Soc 2001;49(9):1190–6.
28. CampbellSS, KripkeDF, GillinJC, HrubovcakJC. Light exposure in healthy elderly subjects and Alzheimer’s patients. Sleep Res 1987;16:327.
29. ShochatT, MartinJ, MarlerM, Ancoli-IsraelS. Illumination levels in nursing home patients: effects on sleep and activity rhythms. J Sleep Res 2000;9:373–9.
30. MoritaT, TokuraH. The influence of different wavelengths of light on human biological rhythms. Appl Human Sci 1998;17(3):91–6.
31. GlickmanG, HanifinJP, RollagMD, et al. Inferior retinal light exposure is more effective than superior retinal exposure in suppressing melatonin in humans. J Biol Rhythms 2003;18(1):71–9.
32. Van SomerenEJW, KesslerA, MirmiranM, SwaabDF. Indirect bright light improves circadian rest-activity rhythm disturbances in demented patients. Biol Psychiatry 1997;41:955–63.
33. SloanePD, WilliamsCS, MitchellCM, et al. High-intensity environmental light in dementia: effect on sleep and activity. J Am Geriatr Soc 2007;55(10):1524–33.
34. DumontM, BeaulieuC. Light exposure in the natural environment: relevance to mood and sleep disorders. Sleep Med 2007;8(6):557–65.
35. TermanM. Evolving applications of light therapy. Sleep Med Rev 2007;11(6):497–507.
36. Fontana GasioP, KrauchiK, CajochenC, et al. Dawn-dusk simulation light therapy of disturbed circadian rest-activity cycles in demented elderly. Exp Gerontol 2003;38(1–2):207–16.
37. FigueiroMG, ReaMS, EgglestonG. Light therapy and Alzheimer’s disease. Sleep Rev 2003;January–February:24–25, 45.
38. GallinPF, TermanM, RemeCE, et al. Ophthalmologic examination of patients with seasonal affective disorder, before and after bright light therapy. Am J Ophthalmol 1995;119(2):202–10.
39. Ancoli-IsraelS, MartinJI, GehrmanP, et al. Effect of light on agitation in institutionalized patients with severe Alzheimer disease. Am J Geriatr Psychiatry 2003;11(2):194–203.
40. LehrlS, GerstmeyerK, JacobJH, et al. Blue light improves cognitive performance. J Neural Transm 2007;114(4):457–60.
41. DowlingGA, GrafCL, HubbardEM, LuxenbergJS. Light treatment for neuropsychiatric behaviors in Alzheimer’s disease. West J Nurs Res 2007;29(8):961–75.
42. Cohen-MansfieldJ, Parpura-GillA, GolanderH. Utilization of self-identity roles for designing interventions for persons with dementia. J Gerontol B Psychol Sci Soc Sci 2006;61(4):P202–12.
43. DowlingGA, HubbardEM, MastickJ, et al. Effect of morning bright light treatment for rest-activity disruption in institutionalized patients with severe Alzheimer’s disease. Int Psychoger 2005;17(2):221–236.
44. Van SomerenEJ, Riemersma-Van Der LekRF. Live to the rhythm, slave to the rhythm. Sleep Med Rev 2007;11(6):465–84.
45. TermanM, TermanJS, Light therapy for seasonal and nonseasonal depression: efficacy, protocol, safety, and side effects. CNS Spectr 2005;10(8):647–63; quiz 672.
46. TermanM, TermanJS. Light therapy. In KrygerMH, RothT, DementWC, eds. Principles and Practice of Sleep Medicine, 4th ed. Philadelphia: Elsevier; 2005: pp. 1424–42.

References

1. FoleyDJ, MonjanAA, IzmirlianG, HaysJC, BlazerDG. Incidence and remission of insomnia among elderly adults in a biracial cohort. Sleep 1999;22(Suppl. 2):S373–8.
2. WeissmanMM, GreenwaldS, Nino-MurciaG, DementWC. The morbidity of insomnia uncomplicated by psychiatric disorders. Gen Hosp Psychiatry 1997;19(4):245–50.
3. HohagenF, RinkK, KapplerC, et al. Prevalence and treatment of insomnia in general practice: a longitudinal study. Eur Arch Psychiatry Clin Neurosci 1993;242:329–36.
4. FoleyDJ, MonjanA, SimonsickEM, WallaceRB, BlazerDG. Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. Sleep 1999;22(Suppl. 2):S366–72.
5. PollakCP, PerlickD, LinsnerJP, WenstonJ, HsiehF. Sleep problems in the community elderly as predictors of death and nursing home placement. J Comm Health 1990;15(2):123–35.
6. BuysseDJ, ReynoldsCF. EEG sleep studies in the differential diagnosis of depression and dementia. Geriatr Med Today 1989;8(3):62–81.
7. BuysseDJ, BrowmanKE, MonkTH, et al. Napping and 24-hour sleep/wake patterns in healthy elderly and young adults. J Am Geriatr Soc 1992;40:779–86.
8. FeinbergI. Changes in sleep cycle patterns with age. J Psychiatr Res 1974;10:283–306.
9. HochCC, DewMA, ReynoldsCF, et al. Longitudinal changes in diary- and laboratory-based sleep measures in healthy “old old” and “young old” subjects: a three-year follow-up. Sleep 1997;20(3):192–202.
10. ReynoldsCF, HochCC, BuysseDJ, et al. REM sleep in successful, usual, and pathological aging: the Pittsburgh experience 1980–1993. J Sleep Res 1993;2:203–10.
11. SteriadeM. Cellular substrates of oscillations in corticothalamic systems during states of vigilance. In LydicR, BaghdoyanHA, eds. Handbook of Behavioral State Control: Cellular and Molecular Mechanisms. Boca Raton: CRC Press; 1999: pp. 327–48.
12. RobbinsTW, EverittBJ. Arousal systems and attention. In GazzanigaM, ed. The Cognitive Neurosciences. Cambridge: MIT Press; 1996: pp. 703–20.
13. SteriadeM, McCarleyRW. Brainstem Control of Wakefulness and Sleep. New York: Plenum Press; 1990.
14. CapeEG, JonesBE. Differential modulation of high-frequency gamma-electroencephalogram activity and sleep-wake state by noradrenaline and serotonin microinjections into the region of cholinergic basalis neurons. J Neurosci 1998;18:2653–66.
15. McCormickDA. Cellular mechanisms of cholinergic control of neocortical and thalamic neuronal excitability. In SteriadeM, BiesoldD, eds. Brain Cholinergic Systems. Oxford: Oxford University Press; 1990.
16. SzymusiakR. Magnocellular nuclei of the basal forebrain: substrates of sleep and arousal regulation. Sleep 1995;18(6):478–500.
17. WainerBH, MesulumMM. Ascending cholinergic pathways in the rat brain. In SteriadeM, BiesoldD, eds. Brain Cholinergic Systems. Oxford: Oxford University Press; 1990
18. EdgarDM. Sleep-wake circadian rhythms and aging: potential etiologies and relevance to age-related changes in integrated physiological systems. Neurobiol Aging 1994;15(4):499–501.
19. MooreRY, AbrahamsonEA, Van Den Pol A. The hypocretin neuron system: an arousal system in the human brain. Arch Ital Biol 2001;139:195–205.
20. ChemelliRM, WillieJT, SintonCM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98(4):437–51.
21. NishinoS, RipleyB, OvereemS, LammersGJ, MignotE. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355(9197):39–40.
22. McCarleyRW, HobsonJA. Neuronal excitability modulation over the sleep cycle: a structural and mathematical model. Science 1975;189:58–60.
23. JonesBE. Basic mechanisms of sleep-wake states. In KrygerMH, RothT, DementWC, eds. Principles and Practice of Sleep Medicine, 2nd ed. Philadelphia: W.B.Saunders Company; 1994: pp. 145–62.
24. SteriadeM, BuzsakiG. Parallel activation of thalamic and cortical neurons by brainstem and basal forebrain cholinergic systems. In SteriadeM, BiesoldD, eds. Brain Cholinergic Systems. Oxford: Oxford University Press; 1990: pp. 3–52.
25. NofzingerEA, MintunMA, WisemanMB, KupferDJ, MooreRY. Forebrain activation in REM sleep: an FDG PET study. Brain Res 1997;770:192–201.
26. SanfordLD, RossRJ, MorrisonAR. Serotonergic mechanisms in the amygdala terminate REM sleep. Sleep Res 1995;24:54.
27. BuchsbaumMS, GillinJC, WuJ, et al. Regional cerebral glucose metabolic rate in human sleep assessed by positron emission tomography. Life Sci 1989;45(15):1349–56.
28. MaquetP, DiveD, SalmonE, et al. Cerebral glucose utilization during sleep-wake cycle in man determined by positron emission tomography and [18F]2-fluoro-2-deoxy-D-glucose method. Brain Res 1990;513(1):136–43.
29. MaquetP, PetersJ, AertsJ, et al. Functional neuroanatomy of human rapid-eye-movement sleep and dreaming. Nature 1996;383(6596):163–6.
30. LydicR, BaghdoyanHA, HibbardL, et al. Regional brain glucose metabolism is altered during rapid eye movement sleep in the cat: a preliminary study. J Comp Neurol 1991;304:517–29.
31. NofzingerEA, MintunMA, PriceJ, et al. A method for the assessment of the functional neuroanatomy of human sleep using FDG PET. Brain Res Protocols 1998;2:191–8.
32. NofzingerEA, NicholsTE, MeltzerCC, et al. Changes in forebrain function from waking to REM sleep in depression: preliminary analyses of [18F]FDG PET studies. Psychiatry Res: Neuroimaging 1999;91:59–78.
33. AnderssonJL, OnoeH, HettaJ, et al. Brain networks affected by synchronized sleep visualized by positron emission tomography. J Cereb Blood Flow Metab 1998;18(7):701–15.
34. ReivichM, IsaacsG, EvartsE, KetyS. The effect of slow wave sleep and REM sleep on regional cerebral blood flow in cats. J Neurochem 1968;15(4):301–6.
35. HofleN, PausT, ReutensD, et al. Regional cerebral blood flow changes as a function of delta and spindle activity during slow wave sleep in humans. J Neurosci 199715;17(12):4800–8.
36. KajimuraN, UchiyamaM, TakayamaY, et al. Activity of midbrain reticular formation and neocortex during the progression of human non-rapid eye movement sleep. J Neurosci 1999;19(22):10065–73.
37. MaquetP. Positron emission tomography studies of sleep and sleep disorders. J Neurol 1997;244(4 Suppl. 1):S23–8.
38. MaquetP, DegueldreC, DelfioreG, et al. Functional neuroanatomy of human slow wave sleep. J Neurosci 1997;17(8):2807–12.
39. MeltzerCC, KinahanPE, NicholsTE, et al. Comparative evaluation of MR-based partial volume correction schemes for PET. J Nucl Med 1999;40:2053–65.
40. MeltzerCC, CantwellMN, GreerPJ, et al. Does cerebral blood flow decline in healthy aging? A PET study with partial volume correction. J Nucl Med 2000;48(11):1842–8.
41. NofzingerEA, BuysseDJ, MiewaldJM, et al. Human regional cerebral glucose metabolism during non-rapid eye movement sleep in relation to waking. Brain 2002;125:1105–15.
42. WuM, CarmichaelO, Lopez-GarciaP, CarterCS, AizensteinHJ. Quantitative comparison of AIR, SPM, and the fully deformable model for atlas-based segmentation of functional and structural MR images. Hum Brain Mapp 2006;27(9):747–54.
43. BeningtonJH, HellerHC. Restoration of brain energy-metabolism as the function of sleep. Prog Neurobiol 1995;45(4):347–60.
44. TononiG, CirelliC. Sleep function and synaptic homeostasis. Sleep Med Rev 2006;10(1):49–62.
45. KruegerJM, ObalF, FangJ. Humoral regulation of physiological sleep: cytokines and GHRH. J Sleep Res 1999;8(Suppl. 1):53–9.
46. CajochenC, FoyR, DijkD-J. Frontal predominance of a relative increase in sleep delta and theta EEG activity after sleep loss in humans. Sleep Res Online 1999;2(3):65–9.
47. NofzingerEA, BuysseDJ, GermainA, et al. Increased activation of anterior paralimbic and executive cortex from waking to rapid eye movement sleep in depression. Arch Gen Psychiatry 2004;61(7):695–702.
48. NofzingerEA, BuysseDJ, GermainA, et al. Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry 2004;161(11):2126–31.